Immunomodulators Market Size, Share, Growth, and Industry Analysis, By Type (Immunosuppressant,Immunostimulants), By Application (Oncology,Respiratory,HIV,Others), Regional Insights and Forecast to 2035

Immunomodulators Market Overview

The global Immunomodulators Market size is projected to grow from USD 154688.1 million in 2026 to USD 159483.44 million in 2027, reaching USD 203153.35 million by 2035, expanding at a CAGR of 3.1% during the forecast period.

The global Immunomodulators Market Research Report highlights that the market value reached approximately USD 245.08 billion in 2025, with the immunosuppressants segment accounting for about 51.13 % of total market share that year. The oncology application claimed roughly 46.23 % share in 2024, while cell-surface receptor blockade mechanisms held about 42.34 % of the product mix in 2024. The market also noted that the hospital end-user segment made up approximately 63.45 % of usage in 2024. The oral route of administration accounted for around 55.23 % of the product share in 2024, reflecting strong patient preference for non-parenteral delivery. Over 28 biosimilar regulatory opinions were issued in 2024, including four for key immunomodulators, signalling intensifying competition in mature antibody classes. Further, Middle East & Africa grew by approximately 17 % year-on-year in immunomodulator uptake in 2024 owing to expansion of oncology infrastructure and regional partnerships.

In the USA market segment of the Immunomodulators Industry Report, the U.S. contributed approximately 78 % of the North American market in 2024. North America held about 39.8 % share globally in 2024, and the U.S. portion underscores its dominance. Clinical trials in the U.S. numbered several thousand across novel immunomodulators in 2023–24, and the U.S. organ transplant volume exceeded 48,000 procedures in 2024 (a 3.3 % increase over 2023). The high burden of new cancer diagnoses—exceeding 2 million in the U.S. in 2025—fuels demand for immunomodulator therapies, and roughly 8 % of the U.S. population is estimated to live with an autoimmune disorder, strengthening the market demand and B2B opportunity for specialised immunomodulator suppliers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 46 % of respondents in industry surveys rank increasing autoimmune disease incidence as a driver.
• Major Market Restraint: 32 % of market participants cite high therapy cost levels as the top restraint.
• Emerging Trends: 28 % of pipeline assets are immunostimulants rather than immunosuppressants.
• Regional Leadership: North America held ~39.8 % of global market share in 2024.
• Competitive Landscape: Two leading firms control approximately 22 % of global immunomodulator market share.
• Market Segmentation: The immunosuppressant product type comprises about 52.8 % of the market in 2024.
• Recent Development: In 2024, over 18 million USD in seed funding was raised for targeted immunomodulator startups.

Immunomodulators Market Latest Trends

The Immunomodulators Market Analysis indicates a notable shift toward immunostimulant therapies, with the immunostimulants segment capturing nearly 10 % of newly approved pipeline assets in 2023 and accounting for approximately 40 % of the product-mix growth momentum. Notably, immunosuppressants still held roughly 52.8 % of market share in 2024. In oncology applications, the share climbed to about 41.3 % in the same year, reflecting increased adoption of checkpoint inhibitors and cell-based immunomodulators in tumour treatment. Hospital end-users dominated with nearly 48.6 % share of usage in 2024, thanks to inpatient infusions, while online pharmacy channels constituted less than 5 % but grew year-on-year by double-digit rates. Biosimilars accounted for around 23 % of mature monoclonal antibody classes in 2024, exerting downward price pressure of up to 66 % in developed markets. In the Asia-Pacific region, the share of the market expanded to around 20 % of global volumes by 2024, driven by rising healthcare expenditure and immunotherapy access initiatives.

Immunomodulators Market Dynamics

DRIVER

"Rise in oncology applications and autoimmune disease incidence"

The main driver of market growth is the rising prevalence of cancer and autoimmune diseases. For example, in 2025 the global cancer incidence exceeded 20 million new cases according to estimates, and autoimmune disorders affect close to 1 in 10 individuals in studied populations. This has spurred demand for immunomodulators as therapies to either suppress over-active immune responses (as in autoimmune disorders) or stimulate immune responses (as in cancer). The number of organ transplant procedures globally surpassed 140 000 in 2023, requiring lifelong immunomodulator management. Biologics and monoclonal antibodies now form over 35 % of all newly-approved immunomodulator therapies each year. These drivers create strong B2B demand across pharma companies, contract manufacturers, biologics supply chains and hospital pharmacy networks. As a result, companies supplying immunomodulators or their components are seeing increased procurement, higher volumes of clinical-trial orders and greater demand for immuno-pharmaceutical manufacturing capacity.

RESTRAINT

"High cost of therapies and regulatory complexity"

The main restraint for the immunomodulators market is the cost burden of therapies and layered regulatory scrutiny. Immunomodulator treatments often cost tens of thousands of dollars per patient annually; for example, checkpoint inhibitor regimens may run to six-figure costs in the U.S. Insurance reimbursement constraints and payer push-back (32 % of industry respondents cite cost as the leading barrier) dampen market uptake, especially in emerging markets. Regulatory pathways for novel immunomodulators, particularly cell-based or gene-therapy linked modalities, involve extensive safety-monitoring, black-box-warning requirements and long development timelines. Manufacturing complexity (e.g., aseptic biologics, cold chain logistics) increases overhead, which restrains smaller players and raises entry barriers. In addition, pricing pressure from biosimilars (23 % share in mature antibody classes) compresses margins. These factors limit near-term uptake in price-sensitive markets and raise procurement hurdles for institutions, which impacts B2B contract negotiation and market expansion in certain regions.

OPPORTUNITY

"Expansion in emerging markets and personalised immunotherapy"

The main opportunity resides in geographic expansion into emerging markets and growth of personalised, precision immunomodulator therapies. The Asia-Pacific region is the fastest-growing cohort, with share rising above 20 % of global volumes by 2024, supported by rising healthcare expenditure and regulatory reforms. Many emerging markets still exhibit low penetration of immunomodulator therapies, offering B2B opportunity for pharma companies, contract manufacturing organisations (CMOs) and supply-chain partners. Precision immunotherapy—such as patient-specific T-cell treatments, biomarker-guided checkpoint combinations and gene-engineered immunomodulators—is projected to account for over 30 % of new immunomodulator launches by 2027. This trend opens B2B opportunities in cell-therapy manufacturing platforms, companion-diagnostic partnerships, logistics and specialist hospital infusion services. Additionally, new markets in Middle East & Africa (which saw ~17 % year-on-year growth in 2024) furnish fresh procurement contracts and local-manufacturing alliances, thereby expanding vendor opportunities beyond saturated developed markets.

CHALLENGE

"Supply-chain complexity and manufacturing capacity constraints"

The main challenge facing the immunomodulators market is supply-chain complexity and limited manufacturing capacity, especially for biologics and cell-based therapies. Biologic immunomodulators require sterile manufacturing, cold-chain shipping, and highly controlled logistics; delays or quality failures lead to regulatory non-compliance or patient safety risks. Contract manufacturing capacity has limited incremental availability, with lead-times of 18-24 months for new lines. Raw-material shortages, such as single-use bioreactor consumables and viral-vector reagents, are cited by over 22 % of manufacturers as key bottlenecks. Additionally, managing inventory and forecasting demand for immunomodulators is more complex than for small-molecule drugs due to lot-specific manufacturing and post-market batch traceability. These constraints hamper timely delivery, inflate cost bases and reduce flexibility in scaling supply for new approvals, which in turn hinders broader B2B scaling and acquisition of large institutional contracts.

Immunomodulators Market Segmentation

The Immunomodulators Industry Report covers segmentation by product type and by application. By type, the segments include Immunosuppressants, Immunostimulants, and others. By application, the report analyses Oncology, Respiratory, HIV, and other disease indications.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Immunosuppressants: The immunosuppressants segment held roughly 52.8 % of the global immunomodulators market in 2024, owing to their extensive usage in transplant medicine and in autoimmune conditions. Therapies such as calcineurin inhibitors, mTOR inhibitors, antimetabolites and monoclonal antibodies dominate this category. For example, global organ-transplant numbers exceeded 140 000 in 2023, which drives continuing demand for immunosuppressive immunomodulators to prevent graft rejection. Autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and Crohn’s disease affect millions worldwide—about 8 % of geographies such as the U.S.—requiring long-term immunosuppressive therapy. B2B players supplying immunosuppressant biologics therefore benefit from repeat purchases, hospital pharmacy contracts and long-term standard-of-care treatment protocols. The dominance of immunosuppressants means that B2B strategy needs to address manufacturing scale, pricing pressure from biosimilars (23 % share in mature immunomodulator biologic classes) and global distribution networks.

The Immunosuppressant segment is projected to be worth USD 85,000 million in 2025, representing a 56.7% market share, and expanding at a CAGR of 3.1% through 2034.

Top Five Major Dominant Countries in the Immunosuppressant Application

• United States: Market size USD 23,000 million, share 27.1%, CAGR 3.2%.
• China: Market size USD 12,400 million, share 14.6%, CAGR 3.3%.
• Germany: Market size USD 7,000 million, share 8.2%, CAGR 3.0%.
• Japan: Market size USD 6,500 million, share 7.6%, CAGR 3.1%.
• India: Market size USD 5,800 million, share 6.8%, CAGR 3.3%.

Immunostimulants: The immunostimulants segment is gaining traction and accounts for about 40 % of the product mix in key reports, with pipeline assets representing close to 28 % of new immunomodulator launches in 2023. Immunostimulants include immune checkpoint inhibitors, cytokines, interleukins and vaccine-adjuvant therapies that enhance immune function. In oncology, immunostimulants form a key arm of treatment, with the oncology application segment at approximately 41.3 % share in 2024. These products are increasingly used in infectious disease, HIV, and immunotherapy-adjunct contexts. For instance, the immunostimulant industry was valued at around USD 108.22 billion in 2022 and grew to about USD 113.54 billion in 2023. B2B opportunities include partnerships for co-development of immune-cell therapies, manufacturing of cytokine products, and supply-chain coordination for immune-activation therapies. The growing emphasis on immunostimulants creates scope for companies to enter through immuno-oncology platforms, contract manufacturing of biologics and research partnerships targeting next-generation immune activation.

The Immunostimulants segment is valued at USD 65,036.95 million in 2025, accounting for a 43.3% share, and is forecast to grow at a CAGR of 3.2% until 2034.

Top Five Major Dominant Countries in the Immunostimulants Application

• United States: Market size USD 18,900 million, share 29.0%, CAGR 3.3%.
• China: Market size USD 10,100 million, share 15.5%, CAGR 3.4%.
• Japan: Market size USD 6,800 million, share 10.4%, CAGR 3.2%.
• Germany: Market size USD 5,500 million, share 8.5%, CAGR 3.0%.
• India: Market size USD 4,600 million, share 7.1%, CAGR 3.3%.

BY APPLICATION

Oncology: Within the application dimension, oncology accounts for the largest segment of the immunomodulators market, with share up to 46.23 % in 2024 and about 41.3 % in 2024 per different sources. Immunomodulators are increasingly integral in cancer treatment, including immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), CAR-T cell therapies and cytokine-based treatments. For example, immune checkpoint inhibitors have demonstrated complete response rates of 71 % in select trials for bladder cancer. Oncology’s dominance reflects the shift from conventional cytotoxic therapies to immune-modulating treatments. B2B stakeholders—pharmas, contract development and manufacturing organisations (CDMOs), hospital pharmacy networks—are all part of the value chain. The demand for immunomodulatory products in oncology is propelled by rising incidence of cancer (global new cases exceeded 20 million in 2025), increasing institutional adoption of immunotherapy regimens, and ongoing approvals of combination therapies. The B2B environment is therefore oriented toward high-value biologics supply, diagnostic reagents for immune profiling, and service agreements for infusion and monitoring.

The Oncology segment is expected to reach USD 60,015 million in 2025, expanding to USD 78,900 million by 2034, capturing approximately 40% market share and growing at a CAGR of 3.2%.

Top Five Major Dominant Countries in the Oncology Segment

• United States: Market size USD 18,800 million, share 31.3%, CAGR 3.3%.
• Germany: Market size USD 6,200 million, share 10.3%, CAGR 3.1%.
• China: Market size USD 7,400 million, share 12.3%, CAGR 3.4%.
• Japan: Market size USD 5,000 million, share 8.3%, CAGR 3.2%.
• United Kingdom: Market size USD 4,100 million, share 6.8%, CAGR 3.0%.

Respiratory, HIV: For respiratory and HIV applications, the immunomodulators market has also begun to show meaningful share. The respiratory segment (which includes conditions such as asthma, chronic obstructive pulmonary disease, post-COVID pulmonary complications) is reported to hold around 30 % of the application share in some analyses and shows increasing uptake of immunomodulators in managing chronic inflammation. The HIV segment is cited as the fastest-growing application in some reports, with share varying from ~15 % in earlier years and acceleration in adoption. For example, the “other applications” category captured roughly 19.8 % in 2023. Immunomodulators used in HIV treatment help to restore or enhance immune function in patients with immune-compromised status; as global efforts to eradicate HIV intensify, demand for immune-boosting agents rises. B2B implications include supply of immunomodulatory agents to specialty clinics, contract manufacturing for cytokine-based therapies, and logistics for global distribution to emerging markets. Additionally, device and diagnostic partner firms that support immune-monitoring in HIV and respiratory contexts are relevant stakeholders in this segmentation.

The Respiratory segment is projected to hold USD 33,000 million in 2025, increasing to USD 43,400 million by 2034, with a 22% market share and a CAGR of 3.0%.

Top Five Major Dominant Countries in the Respiratory Segment

• United States: Market size USD 9,800 million, share 29.7%, CAGR 3.1%.
• China: Market size USD 6,100 million, share 18.5%, CAGR 3.2%.
• Germany: Market size USD 4,000 million, share 12.1%, CAGR 3.0%.
• Japan: Market size USD 3,700 million, share 11.2%, CAGR 2.9%.
• India: Market size USD 2,800 million, share 8.5%, CAGR 3.3%.

Immunomodulators Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

In the North American region the Immunomodulators Industry Report shows that North America held approximately 39.8 % of the global immunomodulator market in 2024. Within that, the U.S. accounted for roughly 78 % of the North American share in 2024. The dominance is driven by a high number of organ transplants (over 48,000 in the U.S. in 2024), a large autoimmune disease patient base (around 8 % of U.S. population), and more than 2 million new cancer cases expected in the U.S. in 2025. Hospital pharmacies in the U.S. remain central to immunomodulator distribution, representing around 48.6 % of usage in 2024. The robust healthcare infrastructure, advanced R&D ecosystem and favourable regulatory environment support early adoption of checkpoint inhibitors, cell therapies and biologics. For B2B providers, this region offers premium contracts for biologics manufacturing, infusion-service partnerships and distribution channels, yet also features intense pricing pressure, biosimilar competition and payer resistance.

The North American market is projected to reach USD 58,000 million in 2025, holding a 38.6% market share and growing at a CAGR of 3.2% through 2034, driven by strong R&D and biologics adoption.

North America – Major Dominant Countries

• United States: Market size USD 45,000 million, share 77.6%, CAGR 3.2%.
• Canada: Market size USD 7,200 million, share 12.4%, CAGR 3.1%.
• Mexico: Market size USD 4,300 million, share 7.4%, CAGR 3.0%.
• Cuba: Market size USD 800 million, share 1.4%, CAGR 3.0%.
• Costa Rica: Market size USD 700 million, share 1.2%, CAGR 3.0%.

EUROPE

In Europe the Immunomodulators Market Analysis shows that Europe contributed roughly 29 % of global revenue in 2024, according to one source. Countries such as Germany, UK, and France are key markets. The presence of a well-established healthcare system, strong government reimbursement regimes and focus on research innovation support market penetration. The immunosuppressant product type holds over 50 % share in many European markets, given the high prevalence of autoimmune disorders and organ transplant programmes. In addition, immunostimulants are gaining adoption with oncology immunotherapy launches in Europe. B2B opportunities involve supply of biologics, biosimilar manufacturing, hospital-pharmacy partnerships and specialty clinic distribution. However, compared to North America, Europe faces slower regulatory approvals, pricing constraints and longer reimbursement lag times. Nonetheless, partnerships with European CDMOs, collaboration on late-stage trials and pan-European distribution alliances make the region attractive for mid- to large-scale B2B players.

The European market is valued at USD 45,500 million in 2025, representing a 30.3% market share, and is projected to expand at a CAGR of 3.0% during the forecast period.

Europe – Major Dominant Countries

• Germany: Market size USD 12,000 million, share 26.4%, CAGR 3.0%.
• United Kingdom: Market size USD 9,000 million, share 19.8%, CAGR 3.1%.
• France: Market size USD 7,600 million, share 16.7%, CAGR 3.0%.
• Italy: Market size USD 6,000 million, share 13.2%, CAGR 3.0%.
• Spain: Market size USD 4,800 million, share 10.6%, CAGR 3.0%.

ASIA-PACIFIC

The Asia-Pacific region is the fastest-growing region in the Immunomodulators Market Outlook. By 2024, the region held approximately 20 % of global volumes in some reports, and its share is expanding. Growth is supported by increasing healthcare access, rising incidence of cancer and autoimmune disease in countries such as China and India, and enhanced regulatory harmonisation. For instance, China approved new immunomodulator biologics (such as anti-CD38 antibodies) in 2025, and India is scaling manufacturing capacity for biosimilars. B2B implications include entry via contract manufacturing for biologics, local-manufacturing alliances, technology-transfer deals and wider regional distribution. However, challenges exist around pricing, reimbursement and infrastructure. For CMOs and suppliers, Asia-Pacific presents large volume growth potential and opportunity to establish manufacturing hubs for global supply chains.

The Asian market is forecast to reach USD 35,500 million in 2025, contributing to 23.6% of global share, with a CAGR of 3.3% through 2034 due to expanding healthcare infrastructure and rising chronic disease cases.

Asia – Major Dominant Countries

• China: Market size USD 14,500 million, share 40.8%, CAGR 3.4%.
• Japan: Market size USD 9,800 million, share 27.6%, CAGR 3.2%.
• India: Market size USD 7,200 million, share 20.3%, CAGR 3.4%.
• South Korea: Market size USD 2,600 million, share 7.3%, CAGR 3.1%.
• Australia: Market size USD 1,400 million, share 3.9%, CAGR 3.0%.

MIDDLE EAST & AFRICA

In Middle East & Africa, the Immunomodulators Market Report notes growth of approximately 17 % year-on-year in 2024 for immunomodulatory usage, though the region’s total share remains under 10 %. Key growth drivers include expanded oncology centres in Saudi Arabia, UAE, increased healthcare spending and partnerships with global immunotherapy firms. The immunomodulator uptake is still lower than in developed regions, but B2B opportunities exist via regional hospital procurement, local manufacturing trade-agreements and infusion service contracts. Constraints include regulatory fragmentation, pricing sensitivity and limited manufacturing capacity. For suppliers and service firms, engaging government health-initiatives, establishing local distribution and managing logistics are practical pathways to tap this emerging segment.

The Middle East and Africa market is estimated at USD 11,000 million in 2025, accounting for a 7.5% market share, and is expected to grow steadily at a CAGR of 3.0% through 2034.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: Market size USD 3,100 million, share 28.2%, CAGR 3.0%.
• United Arab Emirates: Market size USD 2,000 million, share 18.2%, CAGR 3.1%.
• South Africa: Market size USD 2,800 million, share 25.5%, CAGR 3.3%.
• Egypt: Market size USD 1,700 million, share 15.5%, CAGR 3.0%.
• Nigeria: Market size USD 1,400 million, share 12.7%, CAGR 3.0%.

List of Top Immunomodulators Market Companies

• Roche
• Amgen Inc.
• Abbott
• Johnson & Johnson
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Merck & Co. Inc.
• Biogen

Top Two Companies with Highest Market Shares

• Roche: Roche stands as the leading company in the global Immunomodulators Market, commanding approximately 10 % of total market share in 2024. The company’s dominance is driven by its extensive immunomodulator portfolio, including monoclonal antibodies, cytokine therapies, and checkpoint inhibitors. Roche has established a robust pipeline with more than 25 active clinical trials in immune-oncology and autoimmune disorders as of 2025. Its biologics manufacturing capacity expanded by nearly 18 % between 2023 and 2024, enabling faster delivery and supply of immunomodulatory drugs to global hospital and specialty-clinic networks. The company’s focus on innovation, combined with strategic collaborations with biotech startups, reinforces its leadership position in the Immunomodulators Industry Report. Roche’s advanced biologics and biosimilar divisions ensure strong penetration across oncology (46 % market segment share) and autoimmune therapeutics, aligning closely with rising B2B demand for advanced immune-regulating drugs and cell-based therapies.
• Novartis AG:Novartis AG ranks as the second-largest player in the Immunomodulators Industry Analysis, holding about 6 % of global market share in 2024. The company’s success stems from its diversified immunomodulator product line, covering both immunosuppressants and immunostimulants, with significant focus on transplant medicine and inflammatory disease management. Novartis currently operates over 30 research programs targeting immune system modulation, including next-generation biologics and RNA-based immunotherapies. Its manufacturing expansion in Europe and Asia-Pacific increased production output by nearly 14 % year-on-year in 2024, enhancing regional accessibility. The company’s R&D expenditure on immunomodulators accounted for approximately 19 % of its total pharmaceutical development budget in 2025, underscoring its strategic commitment to immune-targeted innovation. Through global partnerships and biosimilar portfolio expansion, Novartis AG continues to strengthen its presence in the Immunomodulators Market Outlook, contributing to technological advancement, improved therapeutic access, and robust B2B collaboration across healthcare networks.

Investment Analysis and Opportunities

In the Immunomodulators Market Research content, investment flows into immunomodulator R&D exceeded USD 18 million in seed funding rounds during 2024, with more than 28 new immunostimulant-assets entering Phase I trials in 2023. Across the value chain, biologics manufacturing capital expenditure rose by roughly 12 % in 2024. For B2B investment, opportunities exist in biologics CDMO capacity expansion, biosimilar manufacturing scale-up and regional manufacturing hubs in Asia-Pacific and Middle East. Pipeline assets for immunomodulators number well over 500 across global companies, offering collaborative licensing and co-development deals. Vertical integration of manufacturing and distribution is emerging as a strategic move for pharma firms: over 15 contract manufacturing alliances were established in 2023-24 between large biopharma and regional CDMOs. Investors targeting this market should note that the immunostimulant segment is representing ~40 % of new product launches and may drive differentiated growth, while the established immunosuppressant segment remains ~52-53 % of the market mix. Funding directed to supply-chain platforms, such as cold-chain logistics providers, aseptic-manufacturing automation and immune-profile diagnostics, offers ancillary investment opportunities tied to the immunomodulators sector.

New Product Development

In the Immunomodulators Industry Report, innovation focus is strong, with more than 35 novel immunomodulatory therapies submitted to regulatory agencies in 2023-24. Products under development include an IL-15 agonist showing ~71 % complete response rate in bladder-cancer trials, T-cell therapies approved for synovial sarcoma, and novel checkpoint inhibitors. Technological advancement is also driving over 20 % of new immunomodulator launches using cell-therapy platforms or gene-engineering approaches in 2024. Biosimilar entry is robust: over 23 % of mature antibody classes had biosimilar regulatory opinions in 2024, including four for ustekinumab copies. Manufacturing innovation: companies are investing in automated single-cell manufacturing lines with lead-times reduced by ~30 %. For B2B players this means opportunities in advanced manufacturing, automation, and biologics supply-chain services. Pharmaceutical firms are also increasingly launching combination-therapy immunomodulators: for example, combinations of checkpoint inhibitors plus anti-inflammatory agents are already in Phase II for solid tumours. Personalized immunotherapy is gaining momentum: more than 30 % of immunomodulator launches now include companion diagnostics. Overall, new product development in immunomodulators is reshaping supply-chain, regulatory and manufacturing landscapes and offers strategic B2B entry points in CDMO services, diagnostics, and regional manufacturing partnerships.

Five Recent Developments

• In March 2024, a biotech startup raised USD 18 million in seed funding aimed at developing highly targeted immunomodulators with novel immune-checkpoint mechanisms.
• In January 2023, a collaboration between a pharma company and a biotech firm granted U.S. commercialisation rights for an anti-PD-1 monoclonal antibody, marking a larger cross-border strategic alliance.
• In 2024, over 28 biosimilar regulatory opinions were issued for mature immunomodulator antibodies, including four for ustekinumab, increasing access and competition.
• In 2024 the number of global organ transplant procedures exceeded 140,000, driving increased demand for immunosuppressive immunomodulators and prompting hospital procurement expansions.
• In 2025 a national regulatory authority in China approved a novel immunomodulator biologic (anti-CD38 antibody) for multiple myeloma, underscoring regulatory acceleration and emerging-market penetration.

Report Coverage of Immunomodulators Market

The Immunomodulators Market Outlook Report covers a comprehensive scope of market data, segmentation and competitive analysis. It includes quantitative units such as product type shares (e.g., immunosuppressants at ~52.8 % in 2024), application-based shares (e.g., oncology ~41.3 % in 2024), and regional contributions (e.g., North America ~39.8 % in 2024). The report analyses segmentation by product (immunosuppressants, immunostimulants, others), application (oncology, respiratory, HIV, others), end-users (hospitals, specialty clinics, home-care) and distribution channels (hospital pharmacy, online pharmacy, retail). It presents competitive landscape data such as leading firms’ market shares (e.g., Roche ~10 %, Novartis ~6 %) and recent development activity (e.g., biotech seed funding, biosimilar approvals). The report also provides strategic insights such as investment flows (e.g., over USD 18 million seed funding in 2024), manufacturing and supply-chain challenges (e.g., manufacturing lead-times for biologics ~18-24 months) and regional growth opportunities (e.g., Middle East & Africa growth ~17 % year-on-year in 2024). B2B stakeholders—from pharma companies to CDMOs, hospital systems and logistics firms—can utilise the Immunomodulators Market Research Report for decision-making in strategy, partnerships and supply-chain planning, leveraging detailed metrics on market size, segmentation shares and trends.

Immunomodulators Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 154688.1 Million in 2026
Market Size Value By	USD 203153.35 Million by 2035
Growth Rate	CAGR of 3.1% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Immunosuppressant Immunostimulants By Application : Oncology Respiratory HIV Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample